Physician profile
David Pollock
NPI 1386093805
$764.48
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $100 · 2021: $664.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $130.13 | 2021 | |
| Bausch Health US, LLC | $119.93 | 2021 | |
| Allergan, INC. | $100.18 | 2020 | |
| Teva Pharmaceuticals USA, INC. | $85.09 | 2021 | |
| Vanda Pharmaceuticals INC. | $56.18 | 2021 | |
| Neurocrine Biosciences, INC. | $55.78 | 2021 | |
| Abbvie INC. | $52.07 | 2021 | |
| Adlon Therapeutics L.P. | $43.82 | 2021 | |
| Janssen Pharmaceuticals, INC | $29.74 | 2021 | |
| Neos Therapeutics, Lp | $23.99 | 2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $20.16 | 2021 | |
| Lundbeck LLC | $16.80 | 2021 | |
| Eisai INC. | $16.65 | 2021 | |
| Otsuka America Pharmaceutical, INC. | $13.96 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Pollock listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.